Dr. Lara on the Potential Role of IDO Inhibitors in the Treatment of RCC

Primo N. Lara, MD
Published: Monday, Jul 31, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).

The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).

The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x